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Abstract. Acquired haemophilia A is a serious and potentially fatal bleeding disorder. Diagnosis is 
difficult and maybe delayed due to its rarity. The high mortality rate and the complex nature of 
treatment necessitate patient management at a haemophilia centre, where the required expe
and resources are available. Prompt diagnosis is crucial and early initiation of therapy could be life 
saving. Management includes initial control of bleeding followed by an approach to eradicate the 
coagulation  factor  inhibitor.  In  this  paper  we  des
haemophilia  A,  which  resulted  in  the  successful  control  of  major bleeding  at  presentation  and 
eradication of inhibitors.
Introduction.  Acquired  haemophilia  A  (AHA)  is  a 
rare  but  often  fatal  bleeding  disorder.
typically lack previous or family history of bleeding. 
Presentation  is  acute  with  sudden  onset  of  bleeding, 
spontaneously or following a hemostatic
contrast  to  congenital  haemophilia,  which  is 
characterized  by  hemarthrosis,  bleeding  in  patients 
with  AHA  commonly  affects  soft  tissue.
associated  with  a  high  mortality  rate  of  9
untreated.
2 Prompt  diagnosis  and  management  ar
important for a favorable outcome.
In this paper we describe our local experience with 
idiopathic  AHA  demonstrating  the  heterogeneity  of 
clinical  presentation,  prognostic  and  therapeutic 
aspects of this disorder. 
Definition.  AHA  is  caused  by  the  develo
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A is a serious and potentially fatal bleeding disorder. Diagnosis is 
difficult and maybe delayed due to its rarity. The high mortality rate and the complex nature of 
treatment necessitate patient management at a haemophilia centre, where the required expe
and resources are available. Prompt diagnosis is crucial and early initiation of therapy could be life 
saving. Management includes initial control of bleeding followed by an approach to eradicate the 
coagulation  factor  inhibitor.  In  this  paper  we  describe  our  local  experience  with  acquired 
haemophilia  A,  which  resulted  in  the  successful  control  of  major bleeding  at  presentation  and 
Acquired  haemophilia  A  (AHA)  is  a 
rare  but  often  fatal  bleeding  disorder.
1 Patients 
typically lack previous or family history of bleeding. 
Presentation  is  acute  with  sudden  onset  of  bleeding, 
spontaneously or following a hemostatic challenge.  In 
contrast  to  congenital  haemophilia,  which  is 
characterized  by  hemarthrosis,  bleeding  in  patients 
with  AHA  commonly  affects  soft  tissue.
2 AHA  is 
associated  with  a  high  mortality  rate  of  9-22%  if 
Prompt  diagnosis  and  management  are 
In this paper we describe our local experience with 
idiopathic  AHA  demonstrating  the  heterogeneity  of 
clinical  presentation,  prognostic  and  therapeutic 
AHA  is  caused  by  the  development  of 
auto-antibodies  against  coagulation  factor  VIII. 
Although  the  most  common  acquired  coagulation 
factor  inhibitors  are  those  directed  against  FVIII, 
inhibitors to other coagulation factors, including factor 
V, and factor IX have also been descri
Genetic  basis: Factor  VIII  is  synthesized  as  a  330
KDa-precursor protein with an A1
C1-C2 domain structure.
4 After proteolytic processing, 
FVIII associates with von Willebrand Factor (VWF) in 
heterodimers. FVIII functions  as a cofactor to factor 
IXa in the tenase complex (
are  primarily  oligoclonal  or  polyclonal 
immunoglobulins G (IgG1 or IgG4). These antibodies 
are  non-complement  fixing  and  non
immunoglobulins  that bind  FVIII  in  a  time
temperature-dependent manner. Most FVIII 
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A is a serious and potentially fatal bleeding disorder. Diagnosis is 
difficult and maybe delayed due to its rarity. The high mortality rate and the complex nature of 
treatment necessitate patient management at a haemophilia centre, where the required expertise 
and resources are available. Prompt diagnosis is crucial and early initiation of therapy could be life 
saving. Management includes initial control of bleeding followed by an approach to eradicate the 
cribe  our  local  experience  with  acquired 
haemophilia  A,  which  resulted  in  the  successful  control  of  major bleeding  at  presentation  and 
antibodies  against  coagulation  factor  VIII. 
[2]
Although  the  most  common  acquired  coagulation 
factor  inhibitors  are  those  directed  against  FVIII, 
inhibitors to other coagulation factors, including factor 
V, and factor IX have also been described.
3 (Table 1)
Factor  VIII  is  synthesized  as  a  330-
precursor protein with an A1-a1-A2-a2-B-a3-A3-
After proteolytic processing, 
FVIII associates with von Willebrand Factor (VWF) in 
. FVIII functions  as a cofactor to factor 
IXa in the tenase complex (Figure 1). FVIII inhibitors 
are  primarily  oligoclonal  or  polyclonal 
immunoglobulins G (IgG1 or IgG4). These antibodies 
complement  fixing  and  non-precipitating 
bind  FVIII  in  a  time-and 
dependent manner. Most FVIII inhibitors Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 1. Coagulation factor inhibitors and associated disorders
Target 
Coagulation 
Factor
Associated Disorders
V Lymphoproliferative disorders, adenocarcinoma, tuberculosis, aminoglycosides, topical thrombin
IX Systemic lupus erythematosus, acute rheumatic fever, hepatitis, collagen, vascular diseases, multiple scierosis, 
postprostatectomy, and postpartum
XI Autoimmune diseases, prostate carcinoma, chronic lymphocytic leukemia, chlorpromazine
XIII Idiopathic, isoniazed, penicillin
VWF
Autoimmune disorders, monoclonal gammopathies, lymphoproliferative diseases, epidermoid malignancies, 
hypothyroidism, myeloproliferative disorders, and certain medication
II Topical thrombin, idiopathic, autoimmune diseases, procainamide
VII Bronchogenic carcinoma, idiopathic
X Amyloidosis, carcinoma, acute nonlymphocytic leukemia, acute respiratory infections, fungicide exposure, 
idiopathic
bind  to  A2,  A3  or  C2  domains.
5 Anti-C2  domain 
antibodies  disrupt  the  FVII  binding  site  to  both 
phospholipid and VWF, while antibodies to A2 and A3 
domains interfere with FVIII binding to FX and FIXa. 
In  contrast  allo-antibodies  in  congenital  haemophilia 
A,  where  antibodies  inactivate  FVIII  in  first-order 
kinetics, the auto-antibodies in  AHA tend to show a 
rapid  initial  inactivation phase  followed by a  slower 
phase  of  equilibrium  in  a  non-linear  inactivation 
pattern or type II kinetics where some factor VIII can 
usually  be  measured.
6 The  complex  type  II  kinetics 
make it difficult to evaluate the clinical importance of 
the  inhibitor  titer  level  or  the  factor  level.  Recent 
findings  suggest  that  polymorphism  in  immune 
regulatory genes are associated with the incidence of 
AHA. The polymorphic genetic profiles of these genes 
differ between ethnic groups and may partly explain 
the variation observed in different population.
7
Incidence.  The  estimated  incidence  of  AHA  varies 
(0.1-1.5  per  million/population  per  year)
1,2 with  a 
median age at presentation of 65 years.
8
Underlying Diseases. Nearly fifty to sixty percent of 
AHA cases occur spontaneously particularly in elderly 
individuals.
9 Therefore most inhibitors are labeled as 
idiopathic,  yet  several  other  series  and  case  reports
have  suggested  an  underlying  pathology  (Table  2).
2
Figure 1. The coagulation cascadeMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 2. Underlying pathology associated with acquired hemophilia A  
Disease Association Green 1981 Collins 2007
Idiopathic 46.1% 63.3%
Collagen, vascular, and other autoimmune diseases 18.0 16.7
Solid and hematological Malignancies 6.7 14.7
Dermatological Disease 4.5 3.3
Possible drug reaction 5.6 NR
Pregnancy and Postpartum Period 7.3 2.0
Other (infections, vaccinations) 11.8 NR
The  most  commonly  associated  conditions  are 
autoimmune  disorders  (17%),  malignancies  (15%), 
pregnancy  (7-21%),  drugs  hypersensitivity  and 
infections. Autoimmune disorders like systemic lupus 
erythematosus.  Sjogen  syndrome,  and  rheumatoid 
arthritis  have  been  associated  with  AHA.
10-13 Other 
frequently  reported  co-morbidities  are  malignancies 
including  liquid  and solid  tumors. Acquired 
haemophilia is commonly associated with solid tumors 
more  than  lymphoproliferative  diseases.
14-17 Drugs 
including  penicillin  and  interferon  have  also  been 
reportedly associated with AHA.
18-19
The postpartum period is one of the more frequent 
settings in which AHA may occur therefore it should 
be  considered  early  in  the  evaluation  of  unusual 
postpartum bleeding.
20-22 Inhibitors can develop during 
pregnancy or labor leading to postpartum bleeding and 
even requiring hysterectomy.  Recurrences in 
subsequent pregnancies has been reported.
22
Clinical  Presentation: Acquired  hemophilia  is 
characterized by lack of past medical or family history 
of bleeding tendency.
10 There is no gender difference 
except  in  the  younger  age  group  because of its the 
association  with  pregnancy.
20-22 The  majority  of 
patients with AHA present with mucocutaneous type of 
bleeding  including;  skin  hematomas,  epistaxis, 
ecchymoses,  menorrhagia,  gastrointestinal  and 
urological  bleeding.  Hemarthrosis,  typically  seen  in 
congenital haemophilia A is not a feature of AHA.
3,24
Other  manifestations  include;  excessive  bleeding 
following trauma or surgery and occasionally cerebral 
hemorrhage.
25
Diagnosis. Frequent delays in the diagnosis of AHA 
may  occur  owing  to  the  rarity  of  the  disorder  and 
absence  of  family  history  of  bleeding.
2 A  structured 
approach to diagnosis should be implemented to ensure 
prompt  initiation  of  treatment.  (Figure  2)  The 
combination of an isolated prolongation of aPTT with a 
normal  platelet  count,  prothrombin  time  (PT)  and 
thrombin time (TT) in a patient with acute bleeding, 
should  raise  the  suspicion  of  a  coagulation  factor 
inhibitor. Failure to correct the prolonged aPTT after 
mixing with normal plasma at a 1:1 proportion after 
incubation for 2 hours at 37
0C favors the presence of 
inhibitor  rather  than  factor  deficiency.
27 An  APTT 
prolongation of 10-15 second longer than the control is 
strongly  suggestive  of  the  presence  of  inhibitors. 
Furthermore,  the  characteristic  time-depended  nature 
of FVIII antibodies confirms their presence.
28-32 Factor 
VIII activity level should be checked and the antibody 
titer should be quantified using the Bethesda assay.
32,33
The residual FVIII activity after incubation of normal 
plasma  with  serial  dilutions  of  patient  plasma  for  2 
hours at 37
0C is measured to quantify inhibitor titer. 
One  Bethesda  unit  (BU)  per  mL  is  the  amount  of 
inhibitor needed to inactivate 50% of factor activity in 
one  milliliter  of  normal  plasma.  The  Nijmegen 
modification adds buffer to minimize shifts in pH.
33,34
Methods. Data were collected from patient’s medical 
records  after  obtaining  an  informed  consent  and 
approval  of  the  hospital  Ethical  Committee.  Blood 
samples  were  collected  and  processed  according  to 
international standards.
29,32
Case  1. Clinical  presentation: A  15-years-old  girl 
presented to our hospital on the 31
st of March, 2002 
with  hematochezia,  melena  and  menorrhagia.  The 
patient  denied  any  past  history  of  bleeding  and  her 
family history was unremarkable for bleeding disorder. 
She  was  not  receiving  any  medications  and  had  no 
history of recent illness. 
Investigation: Laboratory tests revealed normocytic, 
normochromic  anemia  (haemoglobin  6.3  g/dL),  and 
isolated prolongation of aPTT (118 seconds/ control 31 
seconds). Fibrinogen, PT, and platelet count were all 
within normal range. The aPTT failed to correct with 
normal plasma indicating the presence of inhibitor. She 
had a low factor VIII activity (FVIII: <1 IU/L), and a 
normal  von  Willebrand  factor  (VWF)  level.  Family 
study revealed normal FVIII and VWF level in both 
parents, which excludes true haemophilia in a female Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure 2. Diagnostic approach to a bleeding patient
patient.  The  inhibitor  titer  was  >500  Bethesda  units 
(BU/mL). Investigations for conditions most frequently 
associated  with  the  formation  of  inhibitors;  like 
autoimmune  disorders,  malignancies  and 
dermatological disorders were all negative. Both Upper 
and  lower  gastro-intestinal  endoscopies  revealed  no 
local causes of bleeding.
Management: The  patient  was  started  on 
recombinant  FVII  (rFVII)  (Novoseven®,  Novo 
Nordisk, Denmark) 90 mg/kg, intravenous tranexamic 
acid 1gm 8 hourly and received 2 units of packed red 
blood  cells  (PRBC).  Immune  suppression  by 
cyclophosphamide (100 mg/m
2) and oral prednisolone 
(1 mg/kg) was started after counseling and consent of 
her  parents.  The  patient  received  a  second  dose  of 
rFVIIa  (Novoseven®,  Novo  Nordisk,  Denmark)  and 
her  clinical  picture  improved  objectively  over  the 
following  days  as  evidenced  by  the  cessation  of 
gastrointestinal  bleeding. The  patient  was  discharged 
on  cyclophosphamide  and  tapering  doses  of Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
prednisone.
Follow-up: When  next  seen  in  clinic,  patient 
reported no bleeding manifestations and her menstrual 
cycle was regular. During follow up the  patient was 
given  a  single  dose  of  rVIIa  (Novoseven®,  Novo 
Nordisk, Denmark) 90 g/kg before a scheduled dental 
extraction. Extraction was performed successfully and 
the  patient  had  no  excessive  bleeding  following  the 
procedure.  Laboratory  tests  showed  aPTT  of  40 
seconds, FVIII level of 80 IU/dL and an inhibitor titer 
zero  BU/mL.  Her  parents  had  concerns  about  the 
carcinogenic potential of cyclophosphamide so it was 
discontinued  after  completing  three  month  of  the 
treatment. The patient was followed up for 9 years with 
no evidence of recurrence. 
Case  2.  Clinical  presentation:  A  77-years-old  male 
presented  to  the  emergency  room  with a  massive 
muscle hematoma in the right gluteal region following 
an intramuscular injection on the 5
th of March, 2006. 
He had a past medical history of diabetes, hypertension 
and  chronic  obstructive  pulmonary  disease.  His 
medication  list  included  an  oral  hypoglycemic  agent 
(Glucophage)  and  antihypertensive  medications 
(Amaryl and Captopril). 
Investigation: Initial  laboratory  investigations 
showed  normocytic,  normochromic  anemia 
(hemoglobin 6.5 g/dL) and markedly prolonged aPTT 
(116 seconds/ control 32 seconds).  PT, fibrinogen and 
platelet  count  were  all  within  normal  ranges.  The 
absence of any previous history of bleeding suggested 
an  acquired  hemophilia,  which  was  confirmed  by 
failure of APTT to correct after mixing with normal 
plasma  following 2 hours  of incubation  at  37
0C. 
Plasma F VIII level was very low (F VIII <I IU/dL) 
and the FVIII inhibitor titre was 64 BU/mL.
Management: Despite  the  high  antibody  titer,  the 
patient had  mild bleeding which did not present a life-
threatening situation; therefore no systemic hemostatic 
agents were utilized. He received 2 units of packed red 
blood  cell.  Cyclophosphamide  100mg/m
2 orally  was 
started,  however  steroids  were  not  given  because  of 
comorbid  uncontrolled  hypertension  and  diabetes. 
Anti-phospholipid  antibodies  including  lupus 
anticoagulant, anticardiolipin antibody (IgG and IgM) 
and B2 glycoprotein antibodies (IgG and IgM) were all 
negative.  Computed  Tomography  (CT)  scan  of  the 
chest and abdomen showed a left anterior chest wall 
collection but there was no evidence of an underlying 
malignancy. The hematoma gradually resolved and the 
patient was discharged on cyclophosphamide and did 
not require further transfusions upon follow up.
Follow-up: when seen in cinic 3 months later, the 
patient  had  no  bleeding  and  no treatment- related 
toxicitities.  The  aPTT,  and  FVIII  level  were  both 
within normal range and FVIII inhibitor  was absent. 
Tests  for  antinuclear  antibodies  remained  weekly 
positive  (titer  1:80).  Cyclophosphamide  was  thus 
discontinued  and  the  patient  was  followed  up  for  4 
years with no evidence of recurrence.
Case  3.  Clinical  presentation: A  59-year old  male 
presented to the emergency department complaining of 
tongue  bleeding  and  submental  swelling  on  the 
5/1/2009. He had a history of non-insulin dependent 
diabetes mellitus and benign prostatic hypertrophy and 
he was not on any medication. There was no family 
history of bleeding.
Investigations:  the  patient  had severe  normocytic 
normochromic anemia (hemoglobin 6.1 g/dL) and an 
isolated prolongation of aPTT (88 seconds/control 32 
seconds). All other coagulation tests were normal. The 
aPTT  failed  to  correct  upon  mixing  with  normal 
plasma. Factor VIII level was very low (<1 IU/dL) and 
FVIII inhibitor level was 83 BU/mL. 
Management: on the second day of admission, the 
swelling progressed to the submandibular area with the 
development  of  dyspnea,  dysphagia,  hoarseness  of 
voice  and  stridor.  The  ENT  team  performed  nasal 
fibro-optic endoscopy, which revealed a hematoma of 
the tonsils and epiglottis. The patient was immediately 
transferred to intensive care unit (ICU) and started on 
rFVIIa  (Novoseven®,  Novo  Nordisk,  Denmark) 
90g/kg intravenous bolus dose. Dexamethasone (8 mg 
IV twice daily) and tranexamic acid (1 gm IV every 8 
hours) were started and four units of packed red blood 
cells  were transfused.  A  second  dose  of  rFVIIa  was 
required  3  hours  later  to  stop  the  bleeding.  The 
submandibular  swelling  subsided,  and  the  patient 
regained  his  voice.  He  was  discharged  on  day  7  on 
prednisolone  1mg/kg  and  cyclophosphamide  100 
mg/m
2 orally.  The  search  for  an  underlying  disorder 
did not identify a culprit. 
Follow-up: Upon  follow-up  in  the  hematology 
clinic 6 weeks later, his aPTT was 31.1 seconds, F VIII 
was 80 IU/dL and FVIII inhibitor was undetectable. He 
continued on cyclophosphamide and prednisone taper. 
Both medications were discontinued after 6 months of 
treatment and the patient was followed up for 2 years
and remained in haematological remission. Laboratory 
data are presented in Table 3. 
Discussion. These cases confirm the heterogeneity of 
AHA from the  etiologic and clinical points of view. 
Meta-analysis of retrospective and prospective surveys 
on  patients  with  AHA  identified  three  prognostic 
factors  independently  associated  with  a  decreased 
overall  survival.
1,36 These  factors  were:  age,  related 
conditions  (e.g.  malignancy,  post-partum  period  and 
others), and achievement of complete remission. Our Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 3: Laboratory values for patients before and after treatment
Case 1 2 3
Before After Before After Before After
PT Sec 12 12 13 12.5 12.4 12.2
aPTT Sec 218 92 126 36 88 31
FVIII <1U/dL 79 U/dL <1U/dL 87<U/dL <1U/dL 80<U/dL
Bethesala BU/ml 500 0 64 0 83 0
cases  are  in  the  line  with  this  evidence;  in  fact  all 
patients were diagnosed as idiopathic AHA and they 
achieved  a  complete  remission  and  had  a  long-term 
survival.  Cases  2  and  3  were  elderly,  which  is 
inparallel with the median age of presentation. Case 2
had borderline positive test for antinuclear, antibodies, 
but  had  no  underlying  autoimmune  disorder.  The 
appearance of a coagulation factor inhibitor may herald 
the clinical onset of on autoimmune disease by several 
years.  However  the  patient  was  followed up  for  6 
years, which favors the diagnosis of idiopathic AHA. 
Novoseven®  was  used  safely  and  effectively  for 
management of severe bleeding episode in two cases. 
Tranexamic acid proved effective in cases I and 3 as an 
adjuvant therapy for treating hemorrhage in areas with 
high fibrinolytic activity, like the oral cavity and the 
uterus.  All  cases  responded  favorably  to  the 
combination of steroids and cyclophosphamide as first 
line treatment for inhibitor eradication. 
Case  1  was  a  young  female  who, due  to  the 
potential risk of secondary leukaemia associated with
cyclophosphamide, she  elected  to  discontinue it.
Rituximab would have been a good option for her, but 
it  was  not  available  at  the  time  of  her  initial 
presentation. Despite old age of presentation in two of 
the patients, which is usually associated with a poorer
prognosis, these  patients  attained  and  sustained
complete remissions. This highlights the importance of 
epitope characterization in the pathogenesis of AHA. 
All three patients are alive up to the time of writing this 
report. One patient developed an elevated blood sugar 
level  and  worsening  control  of  previously  diagnosed 
non-insulin  dependent  diabetes  mellitus  related  to 
prednisone  therapy.  No  neutropenia,  sepsis, 
thrombocytopenia  or  other  treatment-related 
complications have been observed. 
Management. In contrast  to  congenital haemophilia, 
there  are  no  randomized  studies  on  the  treatment 
options  for  patients  with  AHA,  which  leaves  the 
treatment  decisions  to  the  discretion  of  the  treating 
physician. Management of AHA should be undertaken 
at a haemophilia center where sufficient experience is 
available.
1 Bleeding-related  mortality  rate  is  high 
approaching  15%-20%,
30 which  emphasizes  the 
importance  of  early diagnosis  and  prompt  treatment. 
The aims of the treatment are to control bleeding and to 
eventually  eradicate  the  antibody.  A  conservative
approach and close observation and follow up of the 
titer  for  4-6  weeks  may  be  appropriate  in  children, 
pregnancy  and  drug-associated  AHA  and  in  patients 
with  low  titer  presenting  with  minor  bleeding.
27,28
Management  of  acute  bleeding  should  be  started 
promptly and in a step-wise fashion. Once patient is 
stabilized,  immunosuppressive  therapy  should  be 
started  to  eradicate  the  inhibitor.  Data  on  inhibitor 
eradication,  however,  are  based  on  relatively  small, 
uncontrolled  single-center  cohorts  and  a  meta-
analysis.
35-37
The selection of a treatment option depends on age, 
underlying disorders, bleeding site and severity as well 
as  inhibitor  level.
29,31 Normal  haemostasis  can  be 
achieved by two main mechanisms; use of haemostatic 
agents,  or  FVIII  concentrates.  Haemostatic  agents 
include  Recombinant  FVII,  aPCC,  1-deamino-8-D-
argininevasopressin  DDAVP  and  antifibrinolytic 
agents. Clinical studies have examined the efficacy of 
treatment  options and  good  hameostatic  efficacy  has 
been demonstrated for recombinant activated factor VII 
(rVIIa)  and  factor  VIII  inhibitor  bypass  activity 
(FEIBA). 
Correction of FVIII Level. Correction of FVIII could 
be  achieved  by  human  plasma-derived,  recombinant 
FVIII  concentrate  or  (DDAVP).
37-39  Human  FVIII 
concentrate is the treatment of choice for patients with 
persistently low inhibitor titers (<5 BU/mL) presenting 
with minor bleeds, yet the response is unpredictable.  
The aim of the treatment in patients with minor bleed is 
to keep plasma levels of FVIII of 30-50%.
28,40 It may 
be  advantageous  in  some  cases  to  use  FVIII 
concentrate  that  also  contains  von  Willebrand  factor 
(VWF). For a newly diagnosed patient with a moderate 
or severe bleeding, a high bolus dose of 100-200 IU 
FVIII/kg body weight may be used. Factor level should 
be  determined  at  least  once  daily  to  monitor  the 
laboratory response. However; the clinical response is 
a better guidance in AHA.
Haemostatic  Agents.  Deamino-8-D-arginine 
vasopressin  (DDAVP)  infusion  can  provide  a  rapid, 
albeit transient rise in factor VIII levels in patients with 
very low titer inhibitors, which could be sufficient to 
treat minor bleeding.
38,39 However, DDAVP treatment Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
alone  is  insufficient  to  maintain  hemostasis  in  most 
patients. Tachyphylaxis limits the use of DDAVP on 
consecutive  days  and its  antidiuretic  and  vasomotor 
side effects should be carefully considered in children 
and older patients.
40
In patients  with  high  titer (>10  BU/mL)  or those 
presenting life or limb threatening bleeding factor VIII 
infusion  is  often  unsuccessful.
28,40  These  patients  are 
generally  treated  with  inhibitor  by  pass  therapy. 
Patients who fail to respond to bypass therapy should 
be tried on plasmapheresis
41 and immune-suppressive 
medications
42  or  with  immunoadsorption.
43,44 
Plasmapheresis  alone  or  in  addition  to 
immunoadsorption  of  FVIII  antibodies  using 
staphylococcal  protein  A  may  be  useful  for  patients 
with  high  titer  inhibitors  with  severe  bleeding  or  in 
preparation for surgery who have failed to respond to 
bypassing  agents.  Factor  VIII  replacement  is  needed 
immediately  after  plasmapheresis  to  achieve 
hemeostasis.
By Passing the Inhibitor. By passing the inhibitor can 
be  achieved using activated prothrombin complex  or                                        
recombinant  activated  Factor  VII.  Factor  eight  by 
passing agent (FEIBA) is a virally inactivated, plasma-
derived concentrate of activated clotting factors. The 
mechanism  of  action  of  FEIBA  as  a  bypassing 
concentrate is  not  fully understood.
[45]  Retrospective 
studies  have shown  that  hemostasis  can  be  achieved
with FEIBA in 76% of cases at a dose of 75units/kg, 8 
hourly.
46,47  Clinical  response  is  used  to  monitor 
treatment  due  to  lack  of  a  suitable  method  for 
laboratory monitoring.
40 A total dose of 200 units/kg 
should  not  be  exceeded  within  a  24-hour  period 
because of the risk of thromboembolic complications. 
[48] The  concomitant  use  of  FEIBA  with  systemic 
tranexamic  increases  the  risk  of  thrombosis  and  is 
therefore  not  recommended.
40  Lack  of  clinical 
improvement is an indication for switching to other by 
passing agents.
29,40
Recombinant activated FVIIa binds to tissue factor 
(TF) released at the  site of tissue  injury resulting in 
thrombin  generation  thus  bypassing  the  need  for 
FVIII.
49,50 The  European medicines  Agency  (EMEA) 
concluded  that  rFVIIa’s  benefits  are  great  for  the 
treatment  and  prevention  of  bleeding  episodes  in 
patients  with  congenital  haemophilia  with  inhibitors 
undergoing  surgery,  congenital  factor  VII  deficiency 
and  Glanzmann’s  thrombasthenia.  Recombinant  FVII 
is  given  at  a  dose  of  60-120  mg/kg.  Summer  et  al 
reviewed  139  patients  with  AHA  treated  with  rFVII 
with  an  overall  clinical  response  of  74%. 
[50]
Thromboembolic events have been previously reported 
following the use of rFVII.
51,52  
Therapy  to  Eradicate  FVIII  Inhibitors.  Although 
spontaneous remission  may  occasionally  occur,  most 
published  guidelines  and  treatment  algorithms 
recommend  autoantibody  eradication  once  the 
diagnosis  is  made,  since  bleeding  complications  can 
prove to be fatal.
29,40 Approaches to eradicate inhibitors
include;  immunosuppression,  intravenous 
immunoglobulin  (IVIG)  and plasmapheresis. 
Immunosuppressive therapy is indicated for idiopathic, 
autoimmune  and  malignancy  related  cases.  Data  in 
inhibitor eradication, however, are based on relatively 
small, uncontrolled single-centered cohorts and a meta-
analysis.  Most  centers  have  adopted  a  treatment
regimen consisting of corticosteroids, cytotoxic drugs, 
or  a  combination  of  the  two,  originally  studied  by 
Green  &  Lechner.
10 The  prednisone,  alone  or  in 
combination  with  cyclophosphamide,  azathioprine, 
cyclosporine  or  2-chlorodeoxyadenosine  is 
recommended as first line treatment.
29,40 Prednisone at 
a dose of 1 mg/kg per day for a minimum of six weeks 
followed by a rapid taper of the dose, eradicates the 
inhibitor in 1/3 of the patients.
30 The estimated median 
time to remission is 39 days for steroids alonehowever, 
relapse  is  not  uncommon  (20%)  when 
immunosuppression  is  stopped  or  reduced,  requiring 
the  administration  of  a  second  course.
30 Failure  to 
respond to corticosteroids after a period of 2 to 3 weeks 
calls  for  an  alternative  innumosuppressive  regimen, 
like cyclophosphamide
52-55 or rituximab or both. The 
addition of cyclophosphamide at a dose of 1.5-2 mg/kg 
per  day  at  maximum  3-4  months  can  increase  the 
response rate to 60-80%.
30,55 Cyclophosphamide is best 
avoided  in  women  or  men  in  the  child  bearing age, 
since it has a teratogenic and carcinogenic effect. 
[56,57]
Monitoring  of  side  effects  such  as:  leucopenia, 
thrombocytopenia  and  anemia  is  recommended.  The 
estimated median time to remission is about 49 days 
for  combination  therapy.
30 Rituximab  is  a  chimeric 
monoclonal antibody which targets the CD20 antigen 
on  the  B-cell  lymphocytes.  It  induces  apoptosis 
primarily  in  pre  B-cell  clones  and  has  an 
immunosuppressive mode of action.
58 The off-label use 
of  rituximab has  been studied  in  AHA,  at  a  weekly 
dose of 375 mg/m
2 IV for 4 consecutive weeks showed 
promising results with durable remission particularly in 
patients  with  low  titers.
58-60 Rituximab  alone  or  in 
combination with other modalities is considered as a 
second-line therapy if first-line therapy fails.
29
The  exact  mechanism  of  action  of  intravenous 
immunoglobulins (IVIG)  is  not  fully  understood, 
however  possible  mechanisms  proposed  include 
neutralization caused by the presence of anti-idiotype 
antibodies,  suppression  of  inhibitor  production  and 
temporary displacement of inhibitors. A total dose of 2 
g/kg  over  2  or  5  days  induced  complete  or  partial Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
remission  in  30%  of  patients  particularly  those  with 
low  titers.
62 Multiple courses  are  needed  to  obtain a 
sustained  response.  The  high  cost  of  this  treatment 
makes it a reasonable option as a second line therapy 
for  those  patients  who  fail  to  respond  to 
immunosuppression.  The  value  of  adding  IVIG  to 
immunosuppressive medication to improve the chances 
of inhibitor eradication is controversial.
30
Immune  Tolerance  Induction.  Immune  tolerance  is 
an  accepted  and  effective  treatment  in  patients  with 
congenital  haemophilia  with  inhibitor  but  has  rarely 
been  applied  in  AHA. Complete  and  sustained 
remission  was  achieved  in  more  than  90%  of  the 
patients.
63 The  combination  of  Malmo  and  Bonn 
protocol  (MBMP)  which  includes  immunoadsorption 
and inhibitor elimination, factor VIII substitution, IVIG 
and immunosuppression can reduce the mean time to 
achieve cessation of bleeding to 3 days with MBMP 
protocol compared to 3 weeks for various conventional 
treatment regimes.
64 Complete remission of 88% was 
reported with this protocol.
Prognosis. Patients with AHA have a high mortality 
rate 9-22%.Patients in whom the inhibitor could not be 
eliminated had a higher mortality. Factors predicting a 
favorable response to immunosuppressive therapy are 
low  inhibitor  titers  and  short  interval  between  the 
appearance  of  the  inhibitor  and  initiating  therapy.
30
Low titer inhibitors especially in the early stages are 
more likely to disappear.
30 Younger age is associated 
with better survival and better eradication of inhibitor, 
while older age is associated with poorer outcome and 
a  higher  mortality  rate.
36 The  best  prognosis is  seen 
with  inhibitors  developing  during  the  postpartum 
period, with favorable outcomes reported in 40-97% of 
patients.
36 Eradication of the inhibtor associated with
malignancy is not always possible, but treatment of the 
tumor can  accelerate  inhibitor  eradication.
17,36 The 
relapse rate after CR is about 20%,
30 and median time 
to  relapse  is  around  7  month  after  cessation  of 
therapy.
30,40  Advanced  age,  presence  of  underlying 
malignancy and failure to attain a CR were shown to 
independently affect the mortality.
36
Conclusion. Patients with AHA represent a demanding 
clinical  challenge.  The  morbidity  and  mortality  are 
high,  and  treatment  involves  the  use  of  specific and 
expensive  coagulation  promoting  products.  The 
treatment of the patients with AHA should ideally be at
a  haemophilia  center with  expertise  in  this  area.  No 
standard treatment  protocol  has been defined for  the 
treatment of acute bleeding episodes nor for inhibitor 
eradication and therapy often needs to be individually 
tailored.  FVIII  inhibitors  in  the  cases discussed here 
were totally eradicated with no recurrence despite long 
term follow up, which is unusual for AHA. We believe 
that environmental and genetic factors may play role in 
the  heterogeneity  of  the  disease.  Further  studies  can 
help  identify  the  unique  characteristics  and 
epidemiology of AHA in Saudi Arabia.
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